<bill session="118" type="h" number="5850" updated="2024-07-24T15:20:15Z">
  <state datetime="2023-09-29">REFERRED</state>
  <status>
    <introduced datetime="2023-09-29"/>
  </status>
  <introduced datetime="2023-09-29"/>
  <titles>
    <title type="display">To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.</title>
    <title type="official" as="introduced">To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="M000871"/>
  <cosponsors>
    <cosponsor bioguide_id="M001194" joined="2023-09-29"/>
  </cosponsors>
  <actions>
    <action datetime="2023-09-29">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-09-29" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-10-06">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Abortion"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
</bill>
